The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

Advances in Therapy
Ashok JhaRon Akehurst

Abstract

Inflammatory autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis) have a considerable impact on patients' quality of life and healthcare budgets. Biosimilar infliximab (Remsima(®)) has been authorized by the European Medicines Agency for the management of inflammatory autoimmune diseases based on a data package demonstrating efficacy, safety, and quality comparable to the reference infliximab product (Remicade(®)). This analysis aims to estimate the 1-year budget impact of the introduction of Remsima in five European countries. A budget impact model for the introduction of Remsima in Germany, the UK, Italy, the Netherlands, and Belgium was developed over a 1-year time horizon. Infliximab-naïve and switch patient groups were considered. Only direct drug costs were included. The model used the drug-acquisition cost of Remicade. The list price of Remsima was not known at the time of the analysis, and was assumed to be 10-30% less than that of Remicade. Key variables were tested in the sensitivity analysis. The annual cost savings resulting from the introduction of Remsima were projected to range from €2.89 million (Belgium, 10% discount) to €33....Continue Reading

References

Dec 1, 1992·Arthritis and Rheumatism·L D CarboneL J Melton
Aug 25, 1999·Journal of the American Academy of Dermatology·S R RappD M Reboussin
Dec 13, 2005·Arthritis and Rheumatism·Gunnstein BaklandJan T Gran
Oct 17, 2006·Rheumatology·L J KayUNKNOWN BSR Biologics Register Management committee
Dec 19, 2007·Archives of Dermatology·Consuelo HuertaLuis A García Rodríguez
Dec 25, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·J LundkvistG Kobelt
Jan 31, 2008·Rheumatology International·Maurizio BenucciUNKNOWN Associazione Medici-Scandicci
Jan 1, 2009·F1000 Medicine Reports·John Yost, Johann E Gudjonsson
Dec 3, 2010·Journal of Crohn's & Colitis·A DignassUNKNOWN European Crohn's and Colitis Organisation (ECCO)
Jan 8, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Ewen CumminsElisabeth Fenwick
May 5, 2011·Annals of the Rheumatic Diseases·J BraunD van der Heijde
Sep 29, 2011·Annals of the Rheumatic Diseases·L GossecUNKNOWN European League Against Rheumatism
May 21, 2013·Rheumatology International·Marina Amaral de Ávila MachadoFrancisco de Assis Acurcio
Jul 24, 2013·Clinical Rheumatology·Christian Gissel, Holger Repp
Nov 19, 2013·The New England Journal of Medicine·Niklas NielsenUNKNOWN TTM Trial Investigators
Jan 11, 2014·Annals of the Rheumatic Diseases·Dörte HuscherUNKNOWN German Collaborative Arthritis Centres
May 17, 2014·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Valentin BrodszkyMárta Péntek

❮ Previous
Next ❯

Citations

Mar 5, 2016·Drugs·Filipe AraújoJoão Eurico Fonseca
Mar 1, 2016·Expert Review of Pharmacoeconomics & Outcomes Research·Daniel Resende FaleirosAugusto A Guerra Júnior
Apr 28, 2016·Biologicals : Journal of the International Association of Biological Standardization·Jürgen Braun, Alex Kudrin
Jun 1, 2016·Rheumatology·Niti Goel, Kamali Chance
Mar 11, 2016·Annals of the Rheumatic Diseases·Thomas DörnerGerd R Burmester
Aug 31, 2016·Journal of Crohn's & Colitis·M SeversUNKNOWN initiative of Crohn’s and Colitis
Sep 22, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Hannah A Blair, Emma D Deeks
Oct 13, 2016·Applied Health Economics and Health Policy·August Cesarec, Robert Likić
Nov 4, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ira JacobsSadiq Lula
Jan 18, 2017·Expert Review of Clinical Pharmacology·Sean McConachiePramodini B Kale-Pradhan
Jan 23, 2017·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Carlotta GaleoneAndrea Franchi
Apr 25, 2017·Expert Review of Pharmacoeconomics & Outcomes Research·Fanni RenczValentin Brodszky
Jun 3, 2017·Expert Review of Clinical Immunology·Dae Hyun Yoo
Nov 12, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Mohammed I AladulStephen R Chapman
Apr 27, 2018·Journal of Pediatric Gastroenterology and Nutrition·Neil ChanchlaniRichard K Russell
Jan 3, 2019·Expert Opinion on Biological Therapy·Andras TarnokGabor Veres
Sep 1, 2018·Journal of Pediatric Gastroenterology and Nutrition·Lissy de RidderUNKNOWN Paediatric IBD Porto group of ESPGHAN
May 7, 2019·Expert Opinion on Biological Therapy·Christopher J EdwardsAurelian Amiot
Apr 11, 2017·Current Medicinal Chemistry·Laszlo GulacsiPeter L Lakatos
Mar 14, 2019·Current Pharmaceutical Design·Lorant GoncziPeter L Lakatos
Jul 26, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·Zsombor ZrubkaMárta Péntek
Aug 1, 2019·Journal of Medical Economics·Maurizio Benucci, Fabrizio Cantini
Dec 4, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Binita DuttaSteven Simoens
May 19, 2020·Expert Review of Clinical Immunology·Paolo GisondiGiampiero Girolomoni
Aug 11, 2017·Journal of Medical Economics·Stanton R Mehr, Richard A Brook
Aug 18, 2020·Expert Opinion on Biological Therapy·Tommaso Lorenzo ParigiSilvio Danese
Jul 13, 2016·Current Rheumatology Reports·Filipe C AraújoJoão Eurico Fonseca
Nov 26, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ira JacobsK Lea Sewell
Apr 16, 2019·Frontiers in Pharmacology·Daniel C BaumgartPeter C Taylor
Jun 16, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Seung-Mi LeeDong-Churl Suh
Sep 11, 2019·Inflammatory Bowel Diseases·Andrew W FondellJeffrey S Hyams
Jul 1, 2017·PharmacoEconomics·Steven SimoensLesley G Shane
Feb 9, 2018·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Sascha GerdesMarc A Radtke
Mar 8, 2018·United European Gastroenterology Journal·Petra BajiMárta Péntek

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01217086
NCT01220518

Software Mentioned

PLANETAS
Remicade
Excel
PLANETRA
Remsima

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.